Immunomodulatory activities of α-mangostin on peripheral blood mononuclear cells

• Main Authors: Pimolkan Kasemwattanaroj, Primchanien Moongkarndi, Kovit Pattanapanyasat, Supachoke Mangmool, Ekkarat Rodpai, Jutima Samer, Julaporn Konlata, Kasama Sukapirom
• Other Authors: Mahidol University
• Format: Article
• Published: 2018
• Subjects: Agricultural and Biological Sciences; Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/31109

Mangosteen (Garcinia mangostana L.) a tropical fruit, has been used in traditional medicine. A frequently used part of mangosteen is the pericarp, containing a high content of xanthones. α-Mangostin, one of the major xanthone derivatives, exhibits a variety of actions, including antimicrobial, antioxidant, cytotoxicand antitumor; however, its function on the immune system is still equivocal. This study aimed to examine the immunomodulatory activities of α-mangostin onlymphocyte lineage and cytokine production in human peripheral blood mononuclear cells (PBMCs). The cytotoxic activity of α-mangostin was measured by MTT assay. The concentration of α-mangostin at 5.55 μg/mL resulted in a 50% survival of PBMCs, which was as potent a cytotoxic activity as that of paclitaxel. After 24 h of PBMCs culture, the percentages of T cells (CD3+), B cells (CD19+) and NK cells (CD3-CD16+CD56+) were not significantly changed by treatment with 1, 2 and 4 μg/mL of α-mangostin compared with untreated-PBMCs; in addition, the percentages of these lymphocytes treated with the combination of α-mangostin (1, 2 and 4 μg/mL) and the mitogen concanavalin A (ConA) was not significantly different from that of ConA-treated PBMCs. For cytokine secretion, α-mangostin (1, 2 and 4 μg/mL) did not significantly induce either proinflammatory cytokines (i.e., TNF-α and IL-1β) or cytokine of adaptive immunity (i.e., IL-2). The combination of α-mangostin (1, 2 and 4 μg/mL) and ConA did not significantly alter the relative difference of TNF-α and IL-1β compared with ConA-treated PBMCs; however, these combinations could significantly decrease the relative difference of IL-2 compared with ConA-treated PBMCs. These data indicated that α-mangostin was able to inhibit IL-2 release without interfering with human immune cells; therefore, further studies are necessary to investigate its effect on IL-2 production.